Effect of tobacco avoidance on the incidence of non-hereditary renal cell carcinoma in patients over 18 years of age: systematic review and meta-analysis.

Int Urol NephrolMay 12, 2026 (epub)
Clinical ResearchNephrologyOncology (Medical)Open access

Julián Felipe Valdés Vásquez, Herney Andrés García-Perdomo

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the impact of tobacco avoidance on renal cell carcinoma (RCC) incidence in patients over 18 years without a family history. The analysis included 7 studies with 4,430 patients, revealing that tobacco avoidance was associated with a reduced risk of RCC (RR = 0.69; 95% CI 0.56-0.84).

Key findings

  • Tobacco avoidance was linked to a lower risk of RCC (RR = 0.69; 95% CI 0.56-0.84).
  • Men showed a significant reduction in RCC risk with an RR of 0.52 (95% CI 0.32-0.85).
  • Women had an RR of 0.83 (95% CI 0.48-1.45), indicating a non-significant reduction.

Why it matters

Understanding the relationship between tobacco avoidance and RCC risk is crucial for public health strategies aimed at cancer prevention. This evidence supports the importance of smoking cessation in reducing cancer incidence.

Source

PubMed · PMID 42118473Free full text on PubMed Central

Published in Int Urol Nephrol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.